

# **PROGRAM**

# 2nd Global

# Cell & Gene Therapy Summit

July 07-09, 2025 (Hybrid)

Holiday Inn & Suites - Orlando, FL



SILVER SPONSOR



**EXHIBITOR** 



**EXHIBITOR** 







#### Contact:



### Welcome to CGT Summit 2025

We are thrilled to extend a warm welcome to all participants of the CGT Summit 2025. This summit will bring together exceptional experts from academia and industry, fostering discussions on diverse topics of cell and gene therapy. CGT Summit's comprehensive agenda will feature talks on topics ranging from genome engineering, gene regulation, and viral vector purification to precision gene therapy, cell therapy innovations, and immunotherapy advances.

CGT sessions also list talks on AI-driven decision-making, efficient process development, compliant manufacturing of iPSC-derived therapies, AAV production optimization, closed and automated manufacturing processes with regulatory considerations, public-private partnerships, clinical trial strategies, and the pivotal journey of scaling cell therapies from trials to commercialization.

With a thematic focus on "From Basic Research to CGT Products: Advancing Cell and Gene Therapies through Innovation, Technology, and Collaboration," the summit aims to have meaningful discussions and impactful networking sessions. We look forward to dynamic discussions, insightful presentations, and collaborative endeavors that will undoubtedly drive progress in the realm of cell and gene therapies.



# **EXPERTS @ CGT SUMMIT 2025**



Howard Federoff Chief Medical Officer & Co-Founder Kenai Therapeutics, FL



Sebastien Ribault Chief Commercial Officer Oxford Biomedica, UK



Arun Srivastava
Professor
University of Florida,
FL



Daniel Gibson
Head of Collaborations
Cell and Gene Therapy
Catapult, UK



Rajiv Gangurde Vice President of Technical Operations for CGT Parexel, MA



David Margetts
CEO
Factorytalk Co., Ltd,
Thailand



Arun Upadhyay CSO & Head of Research & Development Ocugen, PA



Lior Shaltiel
CEO
NurExone Biologic,
Israel



Eric Schuur
CEO & Founder
HepaTx
Corporation, CA



Courtney Silverthorn VP, Strategic Alliances and Innovation FNIH, MD



Alicia D. Henn CSO BioSpherix, Ltd., NY



Alex Blyth
Founder & CEO
Lift Biosciences, UK



Alessandra De Riva Head of Process Development and R&D Advent Bioservices, UK



Mehdi Gasmi Chief Operating Officer Sparing Vision, France



Ajit Magadum Assistant Professor University of South Florida, FL

#### **Contact:**



# **EXPERTS @ CGT SUMMIT 2025**



Nathalie Cartier-Lacave VP Neurobiology, CNS Sector Lead Askbio, France



Meg DeAngelis
Endowed Chair & Professor
University at Buffalo,
NY



Neena Haider Founder Shifa Precision, MA



Xiaomo Wu
Head of Regenerative
Medicine & Gene Therapy
Dermatology Institute of
Fuzhou, China



Nidhi Kotecha Program Director, Regulatory Affairs Gates Institute, CO



Anand Srivastava Chairman and Cofounder Global Institute of Stem Cell Therapy and Research, CA



Michael Mehler
Director, Cell Therapy
Operations
AstraZeneca, MA



Vaibhav Patel
Director of QARA
University of Minnesota,
MN



Niranjan Kumar CEO & President ABSINCGROUP, NJ



# Program Outline



#### Day 1, July 07, 2025

**Opening Remarks** 

Genome Engineering, Gene Regulation and Gene Editing Break Throughs

Networking (Coffee) Break

Cell and Gene Therapies for Ocular/Neuro/ Blood Disorders

Cell and Gene Therapies for Rare Diseases

Lunch

Advancements in Cell and Stem Cell-based Therapies

Coffee Break

Gene Therapy: Innovative Platforms, Strategies & Clinical Applications

Precision Gene Therapy for Specific Disorders

\*Social & Networking Dinner (Ticket Required)

#### Day 2, July 08, 2025

CGT Advances in Cancer: Precision Therapies and Immunomodulation

Networking (Coffee) Break

Viral Vector Innovation and Development

Lunch

Advancing CGT Manufacturing: Optimization, Technologies, and Platforms

**Process Development, Manufacturing & Automation** 

Coffee B reak

Optimizing AAV Manufacturing: Engineering, Processing, Analysis and Quality

Control

Poster Presentation and Networking Drinks

#### Day 3, July 09, 2025

Regulatory, Commercialization & Community Engagement

Networking (Coffee) Break

CGT Distribution and Logistics: Optimization, Technologies, and Platforms

Lunch

Panel Discussion I: Next Decade of CGT Research: Future Advancements, Projections,

Challenges, and Innovation

Panel Discussion II: Collaborative Approaches: Industry-Academia Partnerships in CGT

**Manufacturing** 

**Closing Remarks** 

## Day 1 Talks



A Unique Immuno-cell Therapy Platform That Can Overcome IO Treatment Resistance Alex Blyth, Founder & CEO, Lift Biosciences, UK

Nuclease-free Genome Editing with AAV-B19 Hybrid and Chimeric Vectors

Arun Srivastava, George H. Kitzman Professor, University of Florida College of Medicine, FL

Development of Genome-modified NextGen AAV Vectors

Arun Srivastava, George H. Kitzman Professor, University of Florida College of Medicine, FL

mRNA Therapeutics for Cardiovascular Diseases

Ajit Magadum, Assistant Professor, University of South Florida, FL

**TBA** 

**Anand Srivastav,** Chairman and Cofounder, Global Institute of Stem Cell Therapy and Research (GIOSTAR), CA

Modifier Gene Therapy Platform for the Treatment of Ocular Diseases

Arun Upadhyay, CSO & Head of Research & Development, Ocugen, PA

A Novel Proteomic Assay for Monitoring Cell Transplantation

Eric Schuur, Chief Executive Officer & Founder, HepaTx, CA

Considerations for Allogeneic Dopaminergic Cell Products for Parkinson's Disease

**Howard Federoff,** Chief Medical Officer & Co-Founder, Kenai Therapeutics, FL

Pioneering Spinal Cord Injury Treatment: NurExone's Innovative Exosome-Based siRNA Therapy with FDA Endorsement and Expanding Pipeline for Neuronal Regeneration

Lior Shaltiel, Chief Executive Officer, NurExone Biologic, Israel

**TBA** 

Meg DeAngelis, Endowed Chair and Professor, University at Buffalo, NY

**TBA** 

Nathalie Cartier-Lacave, VP Neurobiology, CNS Sector Lead, Askbio, France

**TBA** 

Neena Haider, Founder and CEO Shifa Precision, MA

More talks will be announced soon.....

## Day 2 Talks



From Development to Commercialisation: What is the Key to Success?

Alessandra De Riva, Head of Process Development and R&D, Advent Bioservices, UK

Cytocentric Conditions for Decentralized Biomanufacturing

Alicia Henn, CSO, BioSpherix, Ltd., NY

Digital and Automation: Accelerating Innovation in CGT Industrialisation

**Daniel Gibson,** Head of Collaborations at Cell and Gene Therapy, Catapult, UK

Digitalisation of Cell and Gene Therapies, a Case-study on EBR Deployment for MSC Clinical Trial Production

David Margetts, Chief Executive Officer, Factorytalk Co., Ltd, Thailand

Novel Cell Engineering Platform for High-yield AAV Production and Improved Manufacturability

Larry Forman, Founder and CEO, CHO Plus, Inc., CA

The Need for an Unbiased Assay to Detect and Quantify Replication Competent AAV in Clinical Vector Products

Mehdi GASMI, Chief Operating Officer, Sparing Vision. France

#### **TBA**

Niranjan Kumar, Chief Executive Officer & President, ABSINCGROUP, PA

Overcoming Analytical Challenges for Characterizing AAV-based Drug Products

Rajiv Gangurde, Vice President of Technical Operations for Cell and Gene Therapy, Parexel, MA

Implementing Phase-Appropriate Quality Systems for Cell Therapy: Balancing Flexibility and Compliance

Vaibhav Patel, Director of QARA, University of Minnesota, MN

Viral Vector Innovation: Improving Quality, Productivity, and Gene Size Capacity Sebastien Ribault, Chief Commercial Officer, Oxford Biomedica, UK

AAV8 Encapsidated HMR-005 Mediates High Efficiency of FVIII-BDD Hepatophilic Transduction and Bleeding Normalization in Hemophilic Mice

**Xiaomo Wu,** Head of Regenerative Medicine & Gene Therapy, Dermatology Institute of Fuzhou, China

More talks will be announced soon.....

## Day 3 Talks



Optimizing Technology Transfer and Federal Partnerships to Advance Cell and Gene Therapy Innovation

Courtney Silverthorn, Vice President, Strategic Alliances and Innovation, FNIH, MD

Community Involvment In Cell And Gene Therapy

**Evelyn Harlow,** Uganda National Health Laboratory and Diagnostic Services Ministry of Health, Uganda

Personalized Medicine: Emerging Strategies for Regulatory Challenges

Wala Turkistan, Saudi Food and Drug Authority, Saudi Arabia

**Panel Discussion I:** Next Decade of CGT Research: Future Advancements, Projections, Challenges, and Innovation

**Panel Discussion II:** Collaborative Approaches: Industry-Academia Partnerships in CGT Manufacturing

More talks will be announced soon.....

# Represented by Past Participants



# PRŒEN AMGEN









































#### Contact:



# Represented by Past Participants

















האוניברסיטה העברית בירושלים
THE HEBREW UNIVERSITY OF IERUSALEM







OBSIDIAN THERAPEUTICS







CENTER FOR MEUROSCIENCE AND CELL BIOLOGY UNIVERSITY OF COIMBRA PORTUGAL



















#### Contact:



# CGT 2024 Attendees Demographic

Seniority Level	Percentage (%)
CEO/President/Co-founder	11.76%
VP/Senior VP	5.88%
Director/Deputy Executive Director	14.71%
Senior Manager	1.96%
Project/Program Manager	1.96%
Professor/Chair	9.80%
Scientist/Senior Scientist	28.43%
Business Development Manager	7.84%
Others	17.65%

Continent	Country	Percentage (%)
North America	USA	82.81%
Europe	UK .	5.88%
	Germany	1.96%
	Switzerland	0.98%
	Italy	0.98%
Asia	Israel	1.96%
	China	0.98%
	Taiwan	0.98%
	South Korea	0.98%
	India	0.98%
	Singapore	0.98%
	Hong Kong	0.98%

#### **Contact:**



# Collaborate with CGT Summit 2025





# COLLABORATION PROSPECTS

Forge transformative partnerships with leading researchers, biotech companies, and regulatory experts to advance cell and gene therapy innovations, from discovery to commercialization.

# INDUSTRY INSIGHTS

Gain crucial insights into the latest advancements in CGT, including gene editing breakthroughs, manufacturing optimization, regulatory strategies, and cutting-edge therapeutic applications.



### SHOWCASE OPPORTUNITIES

Highlight your organization's capabilities in CGT by exhibiting groundbreaking technologies, scalable solutions for biomanufacturing, or novel therapeutic platforms to an audience of influential stakeholders.

# POST-CONFERENCE RESOURCES



Access exclusive resources, such as case studies on AAV manufacturing, regulatory guidelines for CGT products, and data from clinical trial advancements, to stay ahead in the rapidly evolving CGT landscape.





## **Register TODAY!**

https://cgtsummit.unitedscientificgroup.org/registration\_form

# For Sponsorship and Exhibitor Opportunities:

Sponsorship/Exhibitor Guide:

https://cgtsummit.unitedscientificgroup.org/pdfs/Exhibitor-Guide.pdf

### For more information:

sanvi@cellgenetherapysummit.com sanvi@cgtsummit.com

+1-469-854-2280/81, +1-844-395-4102

# See You @ CGT SUMMIT-2025 Orlando, FL

#### Contact:

